$KPRX
KIORA PHARMACEUTICALS INC Stock $kprx

$kprx Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000114420415064326 Filed on November 12, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.290M	$950.0K	$280.0K
YoY Change	360.71%	97.92%	-44.0%
% of Gross Profit
Research & Development	$1.380M	$407.6K	$110.0K
YoY Change	1154.55%	265.21%	-15.38%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change			-100.0%
% of Gross Profit
Operating Expenses	$2.680M	$1.354M	$390.0K
YoY Change	587.18%	128.65%	-38.1%
Operating Profit
YoY Change
Interest Expense	-$10.00K	$0.00	$40.00K
YoY Change	-125.0%	-100.0%	-122.22%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$1.785K	$0.00
YoY Change		-82.15%	-100.0%
Pretax Income	-$2.690M	-$1.360M	-$350.0K
YoY Change	668.57%	-488.57%	-55.7%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.690M	-$1.356M	-$420.0K
YoY Change	540.48%	-537.27%	-51.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$269.00	-$136.00	-$42.00
COMMON SHARES
Basic Shares Outstanding	7.655M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.390M	$9.920M	$170.0K
YoY Change	4835.29%	3100.0%	-66.0%
Cash & Equivalents	$8.394M	$9.919M	$167.0K
Short-Term Investments
Other Short-Term Assets	$120.0K	$80.00K	$30.00K
YoY Change	300.0%	300.0%	50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$907.5K		$0.00
Total Short-Term Assets	$9.449M	$10.03M	$218.8K
YoY Change	4219.0%	2765.33%	-60.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$231.00	$1.257K
YoY Change	-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$38.59K	$37.25K	$37.44K
YoY Change	3.07%	-97.04%	-71.2%
Total Long-Term Assets	$58.59K	$61.36K	$1.191M
YoY Change	-95.08%	-95.13%	816.32%
TOTAL ASSETS
Total Short-Term Assets	$9.449M	$10.03M	$218.8K
Total Long-Term Assets	$58.59K	$61.36K	$1.191M
Total Assets	$9.508M	$10.09M	$1.410M
YoY Change	574.31%	526.71%	104.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$417.7K	$160.0K	$565.9K
YoY Change	-26.2%	-42.86%	5559.47%
Accrued Expenses	$1.096M	$250.0K	$913.1K
YoY Change	20.01%	-79.17%	86.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$3.210M
YoY Change	-100.0%	-100.0%	58.13%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.421M	$1.410M	$5.024M
YoY Change	-31.91%	-70.87%	95.49%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.421M	$1.410M	$5.024M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$3.421M	$1.410M	$11.80M
YoY Change	-71.01%	-87.74%	29.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.26M		-$56.86M
YoY Change	14.76%
Common Stock	$76.57K		$2.018K
YoY Change	3694.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.087M	$8.680M	-$46.81M
YoY Change
Total Liabilities & Shareholders Equity	$9.508M	$10.09M	$1.406M
YoY Change	576.0%	526.71%	103.84%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q4
OPERATING ACTIVITIES
Net Income	-$2.690M	-$1.356M	-$420.0K
YoY Change	540.48%	-537.27%	-51.16%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Operating Activities	-$1.550M	-$170.0K	-$440.0K
YoY Change	252.27%	466.67%	-38.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	8.820M	320.0K
YoY Change	-96.88%	-8920.0%
NET CHANGE
Cash From Operating Activities	-1.550M	-170.0K	-440.0K
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	10.00K	8.820M	320.0K
Net Change In Cash	-1.540M	8.650M	-120.0K
YoY Change	1183.33%	-6753.85%	-83.33%
FREE CASH FLOW
Cash From Operating Activities	-$1.550M	-$170.0K	-$440.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	us-gaap	Assets Current AssetsCurrent	10028639	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9919403	USD
CY2015Q3	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2014Q4	us-gaap	Deferred Costs DeferredCosts	1148994	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37250	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	37439	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	218780	USD
CY2015Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	25312	USD
	dei	Trading Symbol TradingSymbol	EYEG
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	26443	USD
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7654644	shares
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	167001	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	83924	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	20000	USD
CY2014Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	25336	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1257	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	231	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	111600	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	407571	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	480450	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	946180	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	592050	USD
CY2014Q3	eyeg	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	-9703	USD
CY2015Q3	eyeg	Research And Development Tax Credit ResearchAndDevelopmentTaxCredit	0	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	89	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	169831	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1987	USD
CY2015Q3	us-gaap	Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple	-1355536	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6741	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1362277	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	1353751	USD
CY2015Q3	us-gaap	Profit Loss ProfitLoss	-1355536	USD
CY2015Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1333118	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1362277	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2668513	USD
	us-gaap	Operating Expenses OperatingExpenses	4001631	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	869245	USD
	us-gaap	Income Loss Before Extraordinary Items And Cumulative Effect Of Change In Accounting Principle IncomeLossBeforeExtraordinaryItemsAndCumulativeEffectOfChangeInAccountingPrinciple	-1199568	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	157928	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8222008	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1357496	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13925160	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.46
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	190516	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5661153	shares
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7687	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	74572	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-1207255	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-5623403	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-55639	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	-32967	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	102289	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-27790	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1309544	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5595613	USD
	us-gaap	Profit Loss ProfitLoss	-1199568	USD
	us-gaap	Profit Loss ProfitLoss	-5697975	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-46806801	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	700462	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-36408666	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18543	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	46782	USD
	eyeg	Stock Issued During Period Value Conversion Of Convertible Securities1 StockIssuedDuringPeriodValueConversionOfConvertibleSecurities1	-6818732	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4099500	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1373858	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	3532694	USD
CY2015Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8677187	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1663873	USD
	eyeg	Reclassification Of Previously Issued Warrant Liability To Stockholders Equity ReclassificationOfPreviouslyIssuedWarrantLiabilityToStockholdersEquity	79930	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	444394	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1292	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1026	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	-1663873	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	25452	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1144856	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-6635	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	57481	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-8810	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-1062	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	718	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-189	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	261965	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-407819	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	944245	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-579179	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6500	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18543	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1189084	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1479202	USD
	eyeg	Proceeds From Convertible Notes Payable ProceedsFromConvertibleNotesPayable	1471374	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-32628	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	288790	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12607973	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	35618	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	74938	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-190074	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9752402	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	501172	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	311098	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	3532694	USD
	eyeg	Conversion Of Non Controlling Interests To Commonstock ConversionOfNonControllingInterestsToCommonstock	0	USD
	eyeg	Conversion Of Non Controlling Interests To Commonstock ConversionOfNonControllingInterestsToCommonstock	6818732	USD
	eyeg	Conversion Of Preferred Stock Into Common Stock ConversionOfPreferredStockIntoCommonStock	0	USD
	eyeg	Conversion Of Preferred Stock Into Common Stock ConversionOfPreferredStockIntoCommonStock	36408666	USD
	eyeg	Exercise Of Common Warrants ExerciseOfCommonWarrants	0	USD
	eyeg	Exercise Of Common Warrants ExerciseOfCommonWarrants	97	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	-876753	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	-223172	USD
	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	79930	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	244111	USD
	us-gaap	Preferred Stock Conversions Inducements PreferredStockConversionsInducements	8222008	USD
	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	1148994	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	113400	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2910509	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-514482	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	20000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-20000	USD
	eyeg	Loss On Cancellation Of Note Receivable And Related Accrued Interest Receivable LossOnCancellationOfNoteReceivableAndRelatedAccruedInterestReceivable	0	USD
	eyeg	Loss On Cancellation Of Note Receivable And Related Accrued Interest Receivable LossOnCancellationOfNoteReceivableAndRelatedAccruedInterestReceivable	-200758	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1364753	USD
	eyeg	Proceeds From Convertible Notes Payable ProceedsFromConvertibleNotesPayable	0	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
CY2015Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.20
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q1	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.4999	pure
CY2014Q4	us-gaap	Minority Interest Ownership Percentage By Parent MinorityInterestOwnershipPercentageByParent	0.4999	pure
CY2014Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5001	pure
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5342137	shares
CY2014Q4	eyeg	Money Market Funds Fair Value MoneyMarketFundsFairValue	187	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	79930	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-223172	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1149000	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	267862	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	266836	USD
	us-gaap	Depreciation Depreciation	1292	USD
	us-gaap	Depreciation Depreciation	1026	USD
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50485136	shares
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	900000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M17D
CY2015Q3	eyeg	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue	849000	USD
CY2015Q3	us-gaap	Area Of Land AreaOfLand	2390	sqft
CY2012Q1	eyeg	License Expiration Period LicenseExpirationPeriod	P12Y
CY2014	eyeg	Net Extinguished Fair Value Of Stock Consideration Received NetExtinguishedFairValueOfStockConsiderationReceived	240000	USD
	us-gaap	License Costs LicenseCosts	12500	USD
CY2012Q1	us-gaap	Payments For Royalties PaymentsForRoyalties	100000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	12500	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1000000	USD
CY2014Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3376573	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
	eyeg	Description On Civil Penalties For Failure To File Fbar DescriptionOnCivilPenaltiesForFailureToFileFbar	greater of $100,000 per year or 50%
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	1144856	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	25452	USD
CY2014	eyeg	Conversion Of Subsidiary Stock Shares Issuable ConversionOfSubsidiaryStockSharesIssuable	1070333	shares
CY2015Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1807203	shares
	eyeg	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageRemainingContractualTerms	P5Y9M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.04
	us-gaap	Preferred Stock Conversion Basis PreferredStockConversionBasis	All outstanding shares of Series A, B, C and D preferred stock automatically converted to common stock immediately upon the closing of the Companys initial public offering in February 2015 at the conversion rates of 1:0.251, 1:0.091, 1:0.091, and 1:0.091, respectively.
CY2015Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	244000	USD
CY2014Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2100000	USD
CY2014Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	240000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	240000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">1. Nature of Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 19.8pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 19.8pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">EyeGate Pharmaceuticals, Inc. (“EyeGate” or the “Company”), a Delaware corporation, began operations in December 2004 and is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EyeGate’s first product in clinical trials incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues though our proprietary innovative drug delivery system, the EyeGate® II Delivery System.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 19.8pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 19.8pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">On February 13, 2015, the Company completed an initial public offering (“the IPO”) for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 683,250</font> shares of common stock. The common stock was offered at an initial price to the public of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.00</font> per share. The gross proceeds to the Company from this offering was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,100,000</font> before deducting underwriting discounts and other estimated offering expenses. The shares began trading on the OTCQB Venture Marketplace under the symbol “EYEG” on February 13, 2015 and the initial offering was closed on February 19, 2015. In related transactions, the Company converted all outstanding notes payable to shareholders and all shares of its convertible preferred stock to shares of common stock. The notes were converted to common shares at the discounted price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.20</font> per share and the <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">preferred shares were converted at the ratio of 10.98 shares of the preferred stock to 1.00 share of common stock</font>. As of September 30, 2015, there are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,654,644</font> shares of common stock outstanding at a par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.01</font>. All preferred stock, shareholder notes and warrant liabilities have been extinguished. On August 5, 2015, the Company closed an underwritten public offering of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,176,470</font> shares of its common stock and warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,176,470</font> shares of its common stock at a combined public offering price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.50</font> per share of common stock and warrant, before underwriting discounts and commissions. The warrants have an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.62</font> per share, are immediately exercisable, and expire on August 5, 2020.  At the closing of the offering, the Company also issued and sold additional warrants to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 176,470</font> shares of common stock in connection with the full exercise of the underwriters’ over-allotment option to purchase additional warrants. The net proceeds to the Company were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8.8</font> million, assuming no exercise of the warrants, and after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 19.8pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 19.8pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Since its inception, EyeGate has devoted substantially all of its efforts to business planning, research and development, and raising capital.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 19.8pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 19.8pt; MARGIN: 0in 0in 0pt"> The accompanying condensed consolidated financial statements have been prepared assuming that EyeGate will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. At September 30, 2015, EyeGate has cash and cash equivalents of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,919,403</font>, and an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">62,565,304</font>. EyeGate has incurred operating losses and negative operating cash flows since inception, and future losses are anticipated. Including the proceeds from the August 5, 2015 closing, the Company will have sufficient cash to fund planned operations for approximately 15 to 18 months, however, the acceleration or reduction of cash outflows by management can significantly impact the timing for raising additional capital to complete development of its products. To continue development, EyeGate will need to raise additional capital through debt and/or equity financing, or access additional funding through grants. Although the Company completed the IPO and Secondary Offering, additional capital may not be available on terms favorable to EyeGate, if at all. Accordingly, no assurances can be given that management will be successful in these endeavors. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should the Company be unable to continue as a going concern.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q1	us-gaap	Conversion Of Stock Description ConversionOfStockDescription	preferred shares were converted at the ratio of 10.98 shares of the preferred stock to 1.00 share of common stock
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10001760	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-1254338	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Use of Estimates</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 19.8pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 19.8pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions are required in providing for fair value of warrants, establishing useful lives of intangible assets and property and equipment, and conducting impairment reviews of long-lived assets. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	eyeg	Conversion Of Stock Conversion Price Per Share ConversionOfStockConversionPricePerShare	6
CY2015Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.20
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1000000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14101260	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	268093	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	268093	USD
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	202000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1597000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	211740	USD
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	60616	shares
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	42431	USD
	us-gaap	Description Of Lessor Leasing Arrangements Operating Leases DescriptionOfLessorLeasingArrangementsOperatingLeases	The Company executed a lease agreement in January 2013 which expired in June 2013. The Company exercised its option to continue the lease on a month to month basis. The agreement is cancellable by either party with one month notice. The Company has executed a new 2 year lease agreement commencing in December 2015 and ending in December 2017
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7654644	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	201787	shares
	eyeg	Convertible Preferred Stock Discount Rate At Initial Public Offering Price ConvertiblePreferredStockDiscountRateAtInitialPublicOfferingPrice	0.3	pure
	eyeg	Debt Conversion Original Debt Discount Rate At Initial Public Offering Price DebtConversionOriginalDebtDiscountRateAtInitialPublicOfferingPrice	0.3	pure

Files In Submission

Name	View Source	Status
0001144204-15-064326-index-headers.html	Edgar Link	pending
0001144204-15-064326-index.html	Edgar Link	pending
0001144204-15-064326.txt	Edgar Link	pending
0001144204-15-064326-xbrl.zip	Edgar Link	pending
eyeg-20150930.xml	Edgar Link	completed
eyeg-20150930.xsd	Edgar Link	pending
eyeg-20150930_cal.xml	Edgar Link	unprocessable
eyeg-20150930_def.xml	Edgar Link	unprocessable
eyeg-20150930_lab.xml	Edgar Link	unprocessable
eyeg-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v424033_10q.htm	Edgar Link	pending
v424033_ex31-1.htm	Edgar Link	pending
v424033_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KPRX
KIORA PHARMACEUTICALS INC Stock $kprx

2015 Q4 Form 10-Q Financial Statement

#000114420415064326 Filed on November 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPRX KIORA PHARMACEUTICALS INC Stock $kprx

2015 Q4 Form 10-Q Financial Statement

#000114420415064326 Filed on November 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KPRX
KIORA PHARMACEUTICALS INC Stock $kprx